News BeiGene abandons TIGIT antibody after lung cancer flop BeiGene has decided to stop the development of its TIGIT-targeting drug ociperlimab in yet another setback for the drug class.
News First drug backed for NHS use in untreated Hodgkin lymphoma Takeda's Adcetris has become the first drug recommended for routine NHS use as a treatment for previously untreated late-stage Hodgkin lymphoma.
News UK first to approve Rotop's prostate cancer imaging agent The UK has given a world-first approval to Rotop's RoTecPSMA, a new imaging agent for detecting lesions in men with prostate cancer.
News MSD says subcutaneous Keytruda matches IV form A formulation of MSD's cancer drug Keytruda that can be given by subcutaneous injection rather than intravenous infusion has cleared a phase 3 trial.
News BIO rings alarm bells over Trump's pharma tariffs US tariffs on goods coming from Europe, China, and Canada could have a major impact on the biopharma industry and medicines access, says BIO.
News J&J throws the gauntlet down to AZ with new survival data New survival data from MARIPOSA for Johnson & Johnson's Rybrevant/Lazcluze combination in lung cancer could spell trouble for AstraZeneca.
News Backers submit plans for £1bn cancer district in London A planning application has been filed to invest £1bn in "the world's leading centre for cancer research and treatment" in a London borough.
Sales & Marketing Sponsored Health Trends 2025: Reimagining What's Possible Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl